Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16688916 | 0.92 | USP30 (0.50) | USP30CSF1RGPR119AAK1FAAH | |
| SCHEMBL16520031 | 0.88 | GPR119 (0.53) | USP30SCN9AGPR119 | |
| SCHEMBL2146881 | 0.88 | USP30 (0.47) | USP30SCN9ACSF1RKDRGPR119 | |
| SCHEMBL19336712 | 0.88 | USP30 (0.47) | USP30SCN9ACSF1RKDRGPR119 | |
| SCHEMBL16520043 | 0.88 | USP30 (0.47) | USP30SCN9ACSF1RKDRGPR119 | |
| SCHEMBL13642308 | 0.84 | USP30 (0.51) | USP30SCN9ACSF1RKDRGPR119 | |
| SCHEMBL23122024 | 0.81 | USP30 (0.49) | USP30CSF1RGPR119AAK1 | |
| SCHEMBL18825434 | 0.81 | USP30 (0.49) | USP30SCN9ACSF1RGPR119AAK1 | |
| SCHEMBL31223016 | 0.81 | USP30 (0.52) | USP30GPR119 | |
| SCHEMBL13642264 | 0.80 | SCN9A (0.52) | SCN9ACSF1RKDRGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSZ | USP30 1503/4885SCN9A 938/4885CSF1R 234/4885 |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | USP30 2758/4885SCN9A 3190/4885CSF1R 303/4885 |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | USP30 3065/4885SCN9A 2973/4885CSF1R 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.